Clinical Trials Directory

Trials / Completed

CompletedNCT01364649

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
447 (actual)
Sponsor
Takeda · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.

Detailed description

The drug being tested in this study is called Lu AA21004. Lu AA21004 is being tested to treat people who have major depressive disorder (MDD). This study will look at sexual function in people who take Lu AA21004. The study will enroll approximately 440 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need): * Lu AA21004 10 to 20 mg * Escitalopram 10 to 20 mg - This is a comparator drug that is also used to treat MDD. All participants will be asked to take one tablet at the same time each day throughout the study. All participants will be asked to answer questionnaires at each study visit. This multi-centre trial will be conducted in the United States and Canada. The overall time to participate in this study is 14 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone 21 days after last dose of study drug for a follow-up assessment.

Conditions

Interventions

TypeNameDescription
DRUGVortioxetineVortioxetine tablets
DRUGEscitalopramEscitalopram tablets
DRUGPlaceboVortioxetine Placebo-matching capsules

Timeline

Start date
2011-06-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2011-06-02
Last updated
2014-10-09
Results posted
2014-10-09

Locations

62 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT01364649. Inclusion in this directory is not an endorsement.